Publications
 
  |
Billioud V, Laharie D, Filippi J, Roblin X, Oussalah A, Chevaux JB, Hebuterne X, Bigard MA, Peyrin-Biroulet L. Adherence to adalimumab therapy in Crohn’s disease: A French multicenter experience. Inflamm Bowel Dis. 2010 Nov 8. |
|
Pillot C, Chevaux JB, Bigard MA, Peyrin-Biroulet L. Infliximab 10 mg/kg every 3 weeks for Crohn’s disease. Am J Gastroenterol. 2010 Nov;105(11):2509-10. |
|
Oussalah A, Laurent V, Bruot O, Gueant JL, Regent D, Bigard MA, Peyrin-Biroulet L. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn’s disease. Aliment Pharmacol Ther. 2010 Nov;32(9):1135-44. doi: |
|
Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourie B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. Am J Gastroenterol. 2010 Aug 24. |
|
Oussalah A, Laurent V, Bruot O, Bressenot A, Bigard MA, Regent D, Peyrin-Biroulet L. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010 Aug;59(8):1056-65. Epub 2010 Jun 4. |
|
Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010 Jun;16(6):916-24. |
|
Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010 May;105(5):1142-9. Epub 2010 Apr 13. |
|
Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010 Aug;16(8):1431-42. – Review |
|
Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, Bretagne JF, Flourie B, Hebuterne X, Bigard MA, Siproudhis L, Peyrin-Biroulet L. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010 Jun;31(11):1178-85. Epub 2010 Mar 8. |
|
Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hebuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lemann M, Colombel JF. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010 Jan;31(1):92-101. Epub . |
|
Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009 Dec;33(12):1082-93. Epub . |
|
Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip JM, Bigard MA, Peyrin-Biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther. 2009 Oct 15;30(8):854-63. |
|
Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Ther. 2009 Oct;30(7):749-56. Epub 2009 Jul 6. |
|
Bigard MA, Siproudhis L. [Anorectal disease: past, present, future] Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):713-23. Epub 2009 Aug 13. |
|
Sanou R, Anxionnat R, Taillandier L, Bigard MA, Regent D, Bracard S. Turcot syndrome: a case report J Radiol. 2009 Jul-Aug;90(7-8 Pt 1):842-4. |
|
Peyrin-Biroulet L, Oussalah A, Bigard MA. Crohn’s disease: the hot hypothesis. Med Hypotheses. 2009 Jul;73(1):94-6. Epub 2009 Mar 6. |
|
Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut. 2009 Apr;58(4):608. – Comment |
|
Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2009 Feb 15;29(4):416-23. Epub 2008 Nov 25. |
|
Peyrin-Biroulet L, Oussalah A, Boucekkine T, Bigard MA. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine. Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):23-30. Epub 2008 Dec 31. |
|
Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L. [Helminths and inflammatory bowel diseases] Gastroenterol Clin Biol. 2008 Dec;32(12):1064-74. Epub 2008 Jul 10. |
|
Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008 Oct 15;28(8):966-72. Epub 2008 Jul 24. |
|
Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, Oussalah A, Seddik M, Canva V, Cortot A, Sogni P, Gueant JL, Bigard MA, Roblin X, Bronowicki JP. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther. 2008 Oct 15;28(8):984-93. Epub 2008 Jul 24. |
|
Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Step-up and top-down approaches to the treatment of Crohn’s disease: early may already be too late. Gastroenterology. 2008 Oct;135(4):1420-2. Epub 2008 Sep 4. – Comment |
|
Bronowicki JP, Abdelmouttalebl D, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Gueant JL. Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa J Hepatol. 2008 Apr;48(4):532-9. Epub 2008 Jan 2. |
|
Chen M, Peyrin-Biroulet L, Xia B, Gueant-Rodriguez RM, Bronowicki JP, Bigard MA, Gueant JL. Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China. BMC Med Genet. 2008 Aug 13;9:78. |
|
Bigard MA. [Therapeutic innovations in gastroesophageal reflux] Presse Med. 2007 Dec;36(12 Pt 3):1907-12. Epub 2007 May 24. – Review |
|
Peyrin-Biroulet L, Oliver A, Bigard MA. Gossypiboma successfully removed by upper-GI endoscopy. Gastrointest Endosc. 2007 Dec;66(6):1251-2. – Comment |
|
Peyrin-Biroulet L, Rodriguez-Gueant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Gueant JL. Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. Am J Gastroenterol. 2007 May;102(5):1108-15. Epub 2007 Mar 13. – Review |
|
Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study World J Gastroenterol. 2007 Apr 28;13(16):2328-32. |
|
Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80. |
|
1 : Indicateurs de santé et évaluation des pratiques en cancérologie
Idrissia ABDELMOUTTALEB